Turn Therapeutics Inc.
Westlake Village, California, United States · Biotechnology, Health Care, Pharmaceutical
Turn Therapeutics® is a concept to approval pharmaceutical and medical device organization dedicated to reducing the human and economic costs of infection and skin disease. Turn Therapeutics® was founded with a goal of reducing antibiotic resistance through best in class acute and chronic wound care products. Through research and development, we have continued to uncover additional disease areas t
Key facts
- Headquarters
- Westlake Village, California, United States
- Employees
- 9
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Status
- Public (TTRX)
- Website
- turntherapeutics.com
- Company page
Recent activity at Turn Therapeutics Inc.
- : SEC 8-K (7.01): On October 6, 2026, Turn Therapeutics Inc. released an updated investor presentation, which is considered a Regulation FD disclosure. This presentation provides key insights and updates to investors regarding the company's operational and financial status. The information is intended to inform shareholders and potential investors about the company's strategic direction and initiatives. The release of this presentation is significant as it aligns with the company's commitment to transparency and engagement with its investors, although it is noted that this information is not intended to be deemed 'filed' with the SEC.
- : SEC 8-K (7.01): On September 10, 2026, Turn Therapeutics Inc. issued a press release disclosing important company information. The press release serves as an important communication to shareholders and the market, although it does not require liability under the Securities Exchange Act. The filing underscores Turn Therapeutics' commitment to transparency, keeping investors informed about its operational or strategic developments, which could signify important shifts within the company. This disclosure is part of the company's obligation as an emerging growth entity and may have implications for stock performance moving forward.
- : SEC 8-K (7.01): On September 9, 2026, Turn Therapeutics Inc. announced important updates via a press release concerning their business operations. The press release outlines recent developments and strategic initiatives the company is undertaking, which may include updates on ongoing projects, partnerships, or financial performance. This disclosure is significant as it provides shareholders and the market insights into the company's current trajectory and future outlook. The press release is included as Exhibit 99.1 in the filing, and while the specifics of the content should be reviewed in that exhibit, it emphasizes the company's commitment to transparency with stakeholders.
- : SEC 8-K (7.01):
- : SEC 8-K (7.01): On July 28, 2026, Turn Therapeutics Inc. published an updated investor presentation aimed at providing important financial and strategic updates to current and potential investors. The presentation includes comprehensive information that may impact investor perceptions and decisions regarding the company. This document is attached as Exhibit 99.1 to the Form 8-K. The filing indicates that this information is furnished and not filed under the Exchange Act, protecting the company from certain liabilities associated with the content. The update likely aims to enhance investor transparency and engagement at a crucial time for the company.
- : SEC 8-K (7.01): On July 7, 2026, Turn Therapeutics Inc. issued a press release and an updated investor presentation. The press release is summarized in Exhibit 99.1, while the investor presentation is included as Exhibit 99.2. Both documents aim to provide stakeholders with updated information about the company's recent developments and financial outlook. This disclosure is aimed at ensuring that investors have access to significant updates that might impact their decisions regarding the company’s securities.
- : SEC 8-K (7.01): On June 1, 2026, Turn Therapeutics Inc. released an updated investor presentation as part of its Regulation FD Disclosure. This presentation, which is furnished as Exhibit 99.1 in the filing, aims to provide insights into the company's current strategies and outlook to investors. The filing emphasizes that the information provided is not considered 'filed' under relevant securities laws, thus limiting legal liability. The document indicates that the presentation itself is dated June 3, 2026, reflecting recent updates which may influence investor perceptions and decisions regarding the company's financial health.
- : SEC 8-K (7.01): On June 1, 2026, Turn Therapeutics Inc. issued a press release to disclose important information to investors and the public. The press release is included as Exhibit 99.1 to the filing and provides updates on significant company developments, enhancing transparency under Regulation FD. This disclosure is crucial for maintaining open communication with stakeholders regarding recent company activities and potential impacts on stock performance. The filing emphasizes that the information provided is not to be considered 'filed' under certain sections of the Securities Exchange Act, thus clarifying its status in regulatory terms.
- : SEC 8-K (7.01): On May 27, 2026, Turn Therapeutics Inc. issued a press release that contains important information for shareholders. The document clarifies that the details within are not considered 'filed' for purposes of regulatory compliance under the Exchange Act. The press release is attached as Exhibit 99.1 and may involve significant updates regarding the company's operations or strategic direction, although specific details from the press release are not provided in the filing. This disclosure is crucial for investors and stakeholders monitoring the company's communications and developments.
- : SEC 8-K (7.01): On May 19, 2026, Turn Therapeutics Inc. issued a press release regarding significant developments concerning the company. The details of the press release may involve updates on corporate strategies, financial performance, or other important information relevant to investors. The press release is attached as Exhibit 99.1 in the filing. This communication is meant to fulfill Regulation FD requirements, ensuring that all investors have equal access to the same material information. This event underscores Turn Therapeutics' commitment to transparency and investor relations.
Turn Therapeutics Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Debt Financing | $25.0M |
| May 2024 | Venture | Undisclosed |
Leadership
- Bradley Rad, Founder/Chief Executive Officer
- Robert R. Redfield, M.D., Chief Scientific Officer
- Stephen M. Hahn, M.D., Chief Regulatory Officer
- Angbeen Chaudhary, Chief of Staff
- Zuraiz Chaudhary, Chief Accounting Officer (CAO)
Verified email and direct lines for Turn Therapeutics Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Turn Therapeutics Inc. in the news
- Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Business Wire (Jul 06, 2026)
- Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum - Yahoo Finance (Sep 10, 2026)
- Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch - Business Wire (Aug 20, 2026)
- Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 - Business Wire (May 19, 2026)
- Turn Therapeutics™ Announces FDA Clearance of Protego™ Antimicrobial Wound Dressing - BioSpace (Oct 11, 2019)
- Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results - Business Wire (Aug 12, 2026)
- Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences - Business Wire (Feb 09, 2026)
- U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat - Business Wire (Oct 21, 2026)
Companies similar to Turn Therapeutics Inc.
- INNOCAN PHARMA Corp · Biotechnology, Health Care, Pharmaceutical, pharmaceuticals
- Kenox Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, pharmaceuticals
- Lupin · Biotechnology, Health Care, Pharmaceutical, pharmaceuticals
- Santhera Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, pharmaceuticals
- Esperion Therapeutics · Biotechnology, Health Care, Pharmaceutical, pharmaceuticals
About Turn Therapeutics Inc.: questions and answers
What does Turn Therapeutics Inc. do?
Turn Therapeutics® is a concept to approval pharmaceutical and medical device organization dedicated to reducing the human and economic costs of infection and skin disease. Turn Therapeutics® was founded with a goal of reducing antibiotic resistance through best in class acute and chronic wound care products. Through research and development, we have continued to uncover additional disease areas t
Where is Turn Therapeutics Inc. headquartered?
Turn Therapeutics Inc. is headquartered in Westlake Village, California, United States.
How many employees does Turn Therapeutics Inc. have?
Turn Therapeutics Inc. has about 9 employees.
Has Turn Therapeutics Inc. raised funding?
Yes. Fundz has recorded 2 funding events for Turn Therapeutics Inc.. The most recent, Debt Financing of $25.0M, was in Mar 2026.
Who leads Turn Therapeutics Inc.?
Bradley Rad is a Founder/Chief Executive Officer at Turn Therapeutics Inc..
What is the latest news on Turn Therapeutics Inc.?
On Oct 06, 2026, SEC 8-K (7.01): On October 6, 2026, Turn Therapeutics Inc. released an updated investor presentation, which is considered a Regulation FD disclosure. This presentation provides key insights and updates to investors regarding the company's operational and financial status. The information is intended
Is Turn Therapeutics Inc. a public company?
Yes. Turn Therapeutics Inc. is publicly traded under the ticker TTRX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy